Kaleido Biosciences (KLDO) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock KLDO vs. XTKG, STIX, STRM, MTC, CXAI, MSGM, HKIT, XTIA, SBET, and BLINShould you be buying Kaleido Biosciences stock or one of its competitors? The main competitors of Kaleido Biosciences include X3 (XTKG), Semantix (STIX), Streamline Health Solutions (STRM), MMTec (MTC), CXApp (CXAI), Motorsport Games (MSGM), Hitek Global (HKIT), XTI Aerospace (XTIA), Sharplink Gaming (SBET), and Bridgeline Digital (BLIN). These companies are all part of the "computer software" industry. Kaleido Biosciences vs. Its Competitors X3 Semantix Streamline Health Solutions MMTec CXApp Motorsport Games Hitek Global XTI Aerospace Sharplink Gaming Bridgeline Digital X3 (NASDAQ:XTKG) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do insiders and institutionals have more ownership in XTKG or KLDO? 1.9% of X3 shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 23.9% of X3 shares are owned by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is XTKG or KLDO more profitable? Company Net Margins Return on Equity Return on Assets X3N/A N/A N/A Kaleido Biosciences N/A N/A N/A Does the media refer more to XTKG or KLDO? In the previous week, X3 had 1 more articles in the media than Kaleido Biosciences. MarketBeat recorded 1 mentions for X3 and 0 mentions for Kaleido Biosciences. X3's average media sentiment score of 1.87 beat Kaleido Biosciences' score of 0.00 indicating that X3 is being referred to more favorably in the media. Company Overall Sentiment X3 Very Positive Kaleido Biosciences Neutral Which has preferable valuation and earnings, XTKG or KLDO? X3 has higher revenue and earnings than Kaleido Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX3$11.61M2.13-$76.24MN/AN/AKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A Which has more risk and volatility, XTKG or KLDO? X3 has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. SummaryX3 beats Kaleido Biosciences on 6 of the 7 factors compared between the two stocks. Get Kaleido Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KLDO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLDO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLDO vs. The Competition Export to ExcelMetricKaleido BiosciencesBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.39M$136.79M$5.69B$9.50BDividend YieldN/A3.74%4.58%4.01%P/E Ratio0.003.7528.1020.05Price / SalesN/A4,471.55432.4490.07Price / CashN/A13.1936.2258.56Price / BookN/A42.328.665.87Net Income-$95.48M-$90.99M$3.25B$258.55M Kaleido Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLDOKaleido BiosciencesN/AN/AN/AN/A$6.39M$1.10M0.0080XTKGX31.1288 of 5 stars$1.82+1.1%N/A-78.5%$24.77M$11.61M0.00200STIXSemantixN/AN/AN/AN/A$23.73M$264.23M0.004STRMStreamline Health Solutions0.5286 of 5 stars$5.30+0.2%N/A-28.0%$23.11M$17.90M-2.32130Positive NewsMTCMMTec1.5074 of 5 stars$0.91+3.4%N/A-63.4%$22.65M$1.87M0.0060Positive NewsCXAICXApp0.8204 of 5 stars$1.08-3.2%N/A-51.1%$21.29M$6.55M-1.122MSGMMotorsport Games1.1678 of 5 stars$3.61-1.2%N/A+75.1%$21.01M$8.69M11.73190News CoverageHKITHitek Global0.6574 of 5 stars$1.38-1.4%N/A-2.1%$19.86M$2.90M0.0075XTIAXTI Aerospace1.0655 of 5 stars$2.07-4.4%N/A-97.3%$19.65M$3.20M0.0012Positive NewsSBETSharplink Gaming1.528 of 5 stars$27.61+9.4%N/A+215.4%$18.07M$3.66M0.0062Gap UpHigh Trading VolumeBLINBridgeline Digital2.4729 of 5 stars$1.51-1.3%$4.62+206.0%+60.6%$17.95M$15.47M-6.5560Gap Up Related Companies and Tools Related Companies X3 Competitors Semantix Competitors Streamline Health Solutions Competitors MMTec Competitors CXApp Competitors Motorsport Games Competitors Hitek Global Competitors XTI Aerospace Competitors Sharplink Gaming Competitors Bridgeline Digital Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLDO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kaleido Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.